Long-term Complete Remission Achieved with TMEp-CI-M Treatment in Refractory Small-Cell Lung Cancer with Brainstem Metastasis

Overview

This case study reports a 60-year-old male with extensive-stage small-cell lung cancer (ES-SCLC) and brainstem metastasis who achieved over 20 months of disease-free survival following treatment with the TMEp-CI-M platform. The regimen included stereotactic body radiotherapy, low-dose etoposide, anlotinib, and a bispecific antibody, resulting in normalization of ProGRP levels.

Background

Brainstem metastasis from small-cell lung cancer is rare and typically associated with poor prognosis. Standard treatment options for extensive-stage SCLC have limited efficacy, highlighting the need for innovative therapeutic strategies. The TMEp-CI-M platform aims to enhance immunotherapy responses in patients with challenging tumor microenvironments.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• The patient achieved no evidence of disease (NED) for over 20 months.
• Treatment included stereotactic body radiotherapy, low-dose etoposide, and anlotinib.
• The bispecific antibody cadonilimab was used for checkpoint inhibition.
• ProGRP levels normalized from 1803 pg/mL to 23.71 pg/mL after the first treatment cycle.
• Only Grade 1 hypothyroidism was reported as an adverse event.

Clinical Implications

The TMEp-CI-M platform may provide a novel approach for treating refractory ES-SCLC, particularly in patients with brainstem metastases. This case suggests that innovative treatment strategies could lead to prolonged disease-free survival in challenging cases.

Conclusion

The successful application of the TMEp-CI-M platform in this case indicates its potential for enhancing immunotherapy efficacy in ES-SCLC. Further studies are needed to validate these findings across larger populations.

Related Resources & Content

1. Bone Marrow Transplantation, Sustained Disease Management of Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma with Central Nervous System Involvement in a Caucasian Individual Following Allogeneic Hematopoietic Cell Transplantation
2. Frontiers in Oncology, Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis
3. Journal of Neuro-Oncology, A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer
4. Journal of Neuro-Oncology, Enhanced Overall Survival in Breast Cancer Patients with Leptomeningeal Metastases Treated Systemically with Bevacizumab, Etoposide, and Cisplatin (BEEP Protocol)
5. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN - PMC
6. Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update - PubMed
7. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting - PMC
8. Current guideline-based management for extensive-stage SCLC
9. Multisociety guidance on brain metastases
10. Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update - PubMed
11. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting - PMC
12. Review of Current Principles of the Diagnosis and Management of Brain Metastases - PMC
13. Second-line treatment outcomes after first-line chemotherapy plus immunotherapy in Extensive-Stage small cell lung cancer (ES-SCLC) patients: A large French multicenter study - ScienceDirect